Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug opdivo qvantig under the microscope: who gets it and how?

NCT ID NCT07636863

Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study reviewed medical records of 200 adults with cancer who received the drug nivolumab (Opdivo) either as an intravenous infusion or as a subcutaneous injection (Opdivo Qvantig) in community oncology clinics across the United States. The goal was to describe the types of patients receiving each form of the drug, how the treatments are used, and any injection- or infusion-related reactions or infections. This is an observational study, meaning it does not test a new treatment but rather gathers information on current real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab (Opdivo) given as an intravenous infusion or as a subcutaneous injection combined with hyaluronidase

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Aug 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with confirmed cancer diagnoses treated with intravenous (IV) nivolumab or subcutaneous (SC) nivolumab + hyaluronidase in U.S. community oncology practices.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are ≥ 18 years of age at the index date * Have a confirmed cancer diagnosis * Received one of the following treatments: * Intravenous (IV) nivolumab * Subcutaneous (SC) nivolumab + hyaluronidase Exclusion Criteria: * Currently receiving a clinical trial therapy at index * Currently receiving treatment for another active concurrent primary cancer diagnosis * Received IV nivolumab or SC nivolumab + hyaluronidase off-label

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida, 33916, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.